ACADIA Pharmaceuticals Inc at Citi BioPharma Conference Transcript
All right. Well, hi, everyone. Thank you so much for taking the time to join Citi's Annual Biopharma Conference. I am Neena Bitritto-Garg, one of the biotech analysts here at Citi. I'm very pleased to be joined for our next fireside chat by the management team from ACADIA Pharmaceuticals. So I have with me the company's CEO, Steve Davis, my company's CFO, Mark.
Questions & Answers
We're actually going to jump directly into Q&A. (Operator Instructions) But I just want to start off with a general question on capital allocation and how you're thinking about that just after the pimavanserin ADP, PDUFA. How should we think about kind of relative prioritization between the commercial franchise with pimavanserin, the R&D pipeline? And recently, I know you've talked a lot about external -- kind of looking at external opportunities, given the market dynamics
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
